Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 121
    records per page




    Proteomics identifies a type I IFN, prothrombotic hyperinflammatory circulating COVID-19 neutrophil signature distinct from non-COVID-19 ARDS

    Authors: Leila Reyes; Manuel Alejandro Sanchez-Garcia; Tyler Morrison; Andrew JM Howden; Emily R Watts; Simone Arienti; Pranvera Sadiku; Patricia Coelho; Ananda S Mirchandani; David Hope; Sarah K Clark; Jo Singleton; Shonna Johnston; Robert Grecian; Azin Poon; Sarah McNamara; Isla Harper; Max Head Fourman; Alejandro J Brenes; Shalini Pathak; Amy Lloyd; Gio Rodriguez Blanco; Alex Von Kriegsheim; Bart Ghesquiere; Wesley Vermaelen; Camila T Cologna; Kevin Dhaliwal; Nik Hirani; David Dockrell; Moira KB Whyte; David M Griffith; Doreen A Cantrell; Sarah R Walmsley; Marc P. Hoeppner; Simon Imm; Ralf Juenker; Sina Kaiser; Ying H. Kan; Rainer Knoll; Christoph Lange; Georg Laue; Clemes Lier; Matthias Lindner; Georgios Marinos; Robert Markewitz; Jacob Nattermann; Rainer Noth; Peter Pickkers; Klaus F. Rabe; Alina Renz; Christoph Roecken; Jan Rupp; Annika Schaffarzyk; Alexander Scheffold; Jonas Schulte-Schrepping; Domagoj Schunck; Dirk Skowasch; Thomas Ulas; Klaus-Peter Wandinger; Michael Wittig; Johannes Zimmermann; Hauke Busch; Bimba F. Hoyer; Christoph Kaleta; Jan Heyckendorf; Matthijs Kox; Jan Rybniker; Stefan Schreiber; Joachim Schultze; Philip Rosenstiel; - HCA Lung Biological Network; - Deutsche COVID-19 Omics Initiative (DeCOI)

    doi:10.1101/2020.09.15.20195305 Date: 2020-09-18 Source: medRxiv

    Understanding the mechanisms by which infection with SARS-CoV-2 leads to acute respiratory distress HP respiratory distress MESHD syndrome ( ARDS MESHD) is of significant clinical interest given the mortality associated with severe and critical coronavirus induced disease MESHD 2019 (COVID-19). Neutrophils play a key role in the lung injury MESHD characteristic of non-COVID-19 ARDS, but a relative paucity of these cells is observed at post-mortem in lung tissue of patients who succumb to infection MESHD with SARS-CoV-2. With emerging evidence of a dysregulated innate immune response in COVID-19, we undertook a functional proteomic survey of circulating neutrophil populations, comparing patients with COVID-19 ARDS, non-COVID-19 ARDS, moderate COVID-19, and healthy controls. We observe that expansion of the circulating neutrophil compartment and the presence of activated low and normal density mature and immature neutrophil populations occurs in both COVID-19 and non-COVID-19 ARDS. In contrast, release of neutrophil granule proteins, neutrophil activation of the clotting cascade and formation of neutrophil platelet aggregates is significantly increased in COVID-19 ARDS. Importantly, activation of components of the neutrophil type I IFN responses is specific to infection with SARS-CoV-2 and linked to metabolic rewiring. Together this work highlights how differential activation of circulating neutrophil populations may contribute to the pathogenesis of ARDS, identifying processes that are specific to COVID-19 ARDS.

    The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study

    Authors: Tarek Sulaiman; Abdulrhman Mohana; Laila Alawdah; Nagla Mahmoud; Mustafa Hassanein; Tariq Wani; Amel Alfaifi; Eissa Alenazi; Nashwa Radwan; Nasser AlKhalifah; Ehab Elkady; Manwer AlAnazi; Mohammed Alqahtani; Khalid Abdalla; Yousif Yousif; Fouad AboGazalah; Fuad Awwad; Khaled AlabdulKareem; Fahad AlGhofaili; Ahmed AlJedai; Hani Jokhdar; Fahad Alrabiah

    doi:10.1101/2020.09.09.20184143 Date: 2020-09-13 Source: medRxiv

    ABSTRACT BACKGROUND: Currently, there is no proven effective therapy nor vaccine for the treatment of SARS-CoV-2. Evidence regarding the potential benefit of early administration of hydroxychloroquine (HCQ) therapy in symptomatic patients with Coronavirus Disease MESHD (COVID-19) is not clear. METHODS: This observational prospective cohort study took place in 238 ambulatory fever HP clinics in Saudi Arabia, which followed the Ministry of Health (MOH) COVID-19 treatment guideline. This guideline included multiple treatment options for COVID-19 based on the best available evidence at the time, among which was Hydroxychloroquine (HCQ). Patients with confirmed COVD-19 (by reverse transcriptase polymerase chain reaction (PCR) test) who presented to these clinics with mild to moderate symptoms during the period from 5-26 June 2020 were included in this study. Our study looked at those who received HCQ-based therapy along with supportive care (SC) and compared them to patients who received SC alone. The primary outcome was hospital admission within 28-days of presentation. The secondary outcome was a composite of intensive care admission (ICU) and/or mortality during the follow-up period. Outcome data were assessed through a follow-up telephonic questionnaire at day 28 and were further verified with national hospitalisation and mortality registries. Multiple logistic regression model was used to control for prespecified confounders. RESULTS: Of the 7,892 symptomatic PCR-confirmed COVID-19 patients who visited the ambulatory fever HP clinics during the study period, 5,541 had verified clinical outcomes at day 28 (1,817 patients in the HCQ group vs 3,724 in the SC group). At baseline, patients who received HCQ therapy were more likely to be males TRANS who did not have hypertension HP hypertension MESHD or chronic lung disease HP lung disease MESHD compared to the SC group. No major differences were noted regarding other comorbid conditions. All patients were presenting with active complaints; however, the HCQ groups had higher rates of symptoms compared to the SC group ( fever HP fever MESHD: 84% vs 66.3, headache HP headache MESHD: 49.8 vs 37.4, cough HP: 44.5 vs 35.6, respectively). Early HCQ-based therapy was associated with a lower hospital admission within 28-days compared to SC alone (9.4% compared to 16.6%, RRR 43%, p-value <0.001). The composite outcome of ICU admission and/or mortality at 28-days was also lower in the HCQ group compared to the SC (1.2% compared to 2.6%, RRR 54%, p-value 0.001). Adjusting for age TRANS, gender TRANS, and major comorbid conditions, a multivariate logistic regression model showed a decrease in the odds of hospitalisation in patients who received HCQ compared to SC alone (adjusted OR 0.57 [95% CI 0.47-0.69], p-value <0.001). The composite outcome of ICU admission and/or mortality was also lower for the HCQ group compared to the SC group controlling for potential confounders (adjusted OR 0.55 [95% CI 0.34-0.91], p-value 0.019). CONCLUSION: Early intervention with HCQ-based therapy in patients with mild to moderate symptoms at presentation is associated with lower adverse clinical outcomes among COVID-19 patients, including hospital admissions, ICU admission, and/or death.

    A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection MESHD in non-human primates

    Authors: Annette Vogel; Isis Kanevsky; Ye Che; Kena Swanson; Alexander Muik; Mathias Vormehr; Lena Kranz; Kerstin Walzer; Stephanie Hein; Alptekin Gueler; Jakob Loschko; Mohan Maddur; Kristin Tompkins; Journey Cole; Bonny Gaby Lui; Thomas Ziegenhals; Arianne Plaschke; David Eisel; Sarah Dany; Stephanie Fesser; Stephanie Erbar; ferdia Bates; Diana Schneider; Bernadette Jesionek; Bianca Saenger; Ann-Kathrin Wallisch; Yvonne Feuchter; Hanna Junginger; Stefanie Krumm; Andre Heinen; Petra Adams-Quack; Julia Schlereth; Christoph Kroener; Shannan Hall-Ursone; Kathleen Brasky; Matthew C Griffor; Seungil Han; Joshua Lees; Ellene Mashalidis; Parag Sahasrabudhe; Charles Tan; Danka Pavliakova; Guy Singh; Camila Fontes-Garfias; Michael Pride; Ingrid Scully; tara Ciolino; Jennifer Obregon; Michal Gazi; Ricardo Carrion; Kendra Alfson; Warren Kalina; Deepak Kaushal; Pei-Yong Shi; Thorsten Klamp; Corinna Rosenbaum; Andreas Kuhn; Oezlem Tuereci; Philip Dormitzer; Kathrin Jansen; Ugur Sahin; Akhilesh Kumar Maurya; K Hemanth; K Nagamani; K Sudha; T Ravi Chandra; K Tushara Rao; J Vyshnavi; Rashmi Upadhyay; Shalini Bahadur; Rambha Pathak; Shikha Seth; Rakesh Gupta; Rita Saxena; Preksha Dwivedi; Reeni Malik; Deepti Chourasia; Jaya Lalwani; UM Sharma; JL Marko; Amit Suri; Vijay Kumar; Rajnish Kaushik; Parul Kodan; Bhabani Prasad Acharya; Kuldeep Kumar Gaur; Anubhav Gupta; Prerna Sachdeva; Shruti Dogra; Aikaj Jindal; M Joseph John; Avtar Singh Dhanju; Ranjana Khetrepal; Neeraj Sharma; Neetu Kukar; Divya Kavita; Rajesh Kumar; Rajesh Mahajan; Gurpreet Singh; Jaspreet Kaur; Raminder Pal Singh; Rajni Bassi; Swapneil Parikh; Om Shrivastav; Jayanthi Shastri; Maherra Desai; Shreevatsa Udupa; Varun A Bafna; Vijay Barge; Rajendra Madane; Sheetal Yadav; Sanjeev Mishra; Archana Bajpayee; M K Garg; G K Bohra; Vijaylakshmi Nag; Puneeth Babu Anne; Mohd Nadeem; Pallavi Singh; Ram Niwas; Niranjan Shiwaji Khaire; Rattiram Sharma; Mini p Singh; Naresh Sachdeva; Suchet Sachdev; Rekha Hans; Vikas Suri; L N Yaddanapudi; PVM Lakshmi; Neha Singh; Divendu Bhushan; Neeraj Kumar; Muralidhar Tambe; Sonali Salvi; Nalini Kadgi; Shashikala Sangle; Leena Nakate; Samir Joshi; Rajesh Karyakarte; Suraj Goyanka; Nimisha Sharma; Nikhil Verma; Asim Das; Monika Bahl; Nitya Wadhwa; Shreepad Bhat; Shweta Deshmukh; Vrushali Wagh; Atul Kulkarni; Tanvi Yardi; Ram S Kalgud; Purushottam Reddy; Kavitha Yevoor; Prashanth Gajula; Vivek Maleyur; Medini S; Mohith HN; Anil Gurtoo; Ritika Sud; Sangeeta Pahuja; Anupam Prakash; Parijat Gogoi; Shailja Shukla; D Himanshu Reddy; Tulika Chandra; Saurabh Pandey; Pradeep Maurya; Ali Wahid; Vivek Kumar; Kamlesh Upadhyay; Nidhi Bhatnagar; Nilima Shah; Mamta Shah; Tarak Patel; Ram Mohan Jaiswal; Ashish Jain; Shweta Sharma; Puneet Rijhwani; Naveen Gupta; Tinkal C Patel; Mahesh G Solu; Jitendra Patel; Yash R Shah; Mayur Jarag; Varsha Godbole; Meenakshi Shah; Rikin Raj; Irfan Nagori; Pramod R Jha; Arti D Shah; Gowtham Yeeli; Archit Jain; Rooppreet Kaur Gill; KV Sreedhar Babu; B Suresh Babu; Alladi Mohan; B Vengamma; K Chandra Sekhar; Srinivasulu Damam; K Narsimhulu; C Aparna; G Baleswari; Ravindranath Reddy K; P Chandrasekhar; Sunil Jodharam Panjwani; Pankaj J Akholkar; Kairavi Parthesh Joshi; Pragnesh H Shah; Manish Barvaliya; Milind Baldi; Ashok Yadav; Manoj Gupta; Nitin Rawat; Dilip Chawda; M Natarajan; M Sintha; David Pradeep Kumar; Fathhur Rabbani; Vrushali Khirid Khadke; Dattatray Patki; Sonali Marathe; Clyde D Souza; Vipul Tadha; Satyam Arora; Devendra Kumar Gupta; Seema Dua; Nitu Chauhan; Ajeet Singh Chahar; Joy John Mammen; Snehil Kumar; Dolly Daniel; Ravindraa Singh; Venkatesh Dhat; Yogesh Agarwal; Sohini Arora; Ashish Pathak; Manju Purohit; Ashish Sharma; Jayashree Sharma; Manisha Madkaikar; Kavita Joshi; Reetika Malik Yadav; Swarupa Bhagwat; Niteen D Karnik; Yojana A Gokhale; Leena Naik; Sangita Margam; Santasabuj Das; Alka Turuk; V Saravana Kumar; K Kanagasabai; R Sabarinathan; Gururaj Deshpande; Sharda Sharma; Rashmi Gunjikar; Anita Shete; Darpan Phagiwala; Chetan Patil; Snehal Shingade; Kajal Jarande; Himanshu Kaushal; Pragya Yadav; Gajanan Sapkal; Priya Abraham

    doi:10.1101/2020.09.08.280818 Date: 2020-09-08 Source: bioRxiv

    To contain the coronavirus disease MESHD 2019 (COVID-19) pandemic, a safe and effective vaccine against the new severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV-2) is urgently needed in quantities sufficient to immunise large populations. In this study, we report the design, preclinical development, immunogenicity and anti-viral protective effect in rhesus macaques of the BNT162b2 vaccine candidate. BNT162b2 contains an LNP-formulated nucleoside-modified mRNA that encodes the spike glycoprotein captured in its prefusion conformation. After expression of the BNT162b2 coding sequence in cells, approximately 20% of the spike molecules are in the one-RBD up, two-RBD down state. Immunisation of mice with a single dose of BNT162b2 induced dose level-dependent increases in pseudovirus neutralisation titers. Prime-boost vaccination of rhesus macaques elicited authentic SARS-CoV-2 neutralising geometric mean titers 10.2 to 18.0 times that of a SARS-CoV-2 convalescent human serum SERO panel. BNT162b2 generated strong TH1 type CD4+ and IFNy+ CD8+ T-cell responses in mice and rhesus macaques. The BNT162b2 vaccine candidate fully protected the lungs of immunised rhesus macaques from infectious SARS-CoV-2 challenge. BNT162b2 is currently being evaluated in a global, pivotal Phase 2/3 trial (NCT04368728).

    Burden and prevalence SERO of risk factors for severe COVID-19 disease in the ageing European population – A SHARE-based analysis

    Authors: Linda Juel Ahrenfeldt; Camilla Riis Nielsen; Sören Möller; Kaare Christensen; Rune Lindahl-Jacobsen

    doi:10.21203/rs.3.rs-73657/v1 Date: 2020-09-07 Source: ResearchSquare

    Aim: International health authorities suggest that individuals aged TRANS 65 years and above and people with underlying comorbidities such as hypertension HP hypertension MESHD, chronic lung disease HP lung disease MESHD, cardiovascular disease MESHD, cancer MESHD, diabetes MESHD, and obesity HP obesity MESHD are at increased risk of severe Coronavirus Disease MESHD 2019 (COVID-19); however, the prevalence SERO of risk factors is unknown in many countries. Therefore, we aim to describe the distribution of these risk factors across Europe. Subject and Methods: Prevalence SERO of risk factors for severe COVID-19 was identified based on interview for 73,274 Europeans aged TRANS 50+ participating in the Survey of Health, Ageing and Retirement in Europe (SHARE) in 2017. Burden of disease was estimated using population data from Eurostat. Results: A total of 75.3% of the study population (corresponding to app. 60 million European men and 71 million women) had at least one risk factor for severe COVID-19, 45.9% (app. 36 million men and 43 million women) had at least two factors and 21.2% (app. 17 million men and 20 million women) had at least three risk factors. The prevalences SERO of underlying medical conditions ranged from 4.5% for cancer MESHD to 41.4% for hypertension HP hypertension MESHD, and the region-specific prevalence SERO of having at least three risk factors ranged from 18.9% in Northern Europe to 24.6% in Eastern Europe. Conclusions: Information about the prevalences SERO of risk factors might help authorities to identify the most vulnerable subpopulations with multiple risk factors of severe COVID-19 disease MESHD and thus to decide appropriate strategies to mitigate the pandemic.  

    Deep-learning convolutional neural networks with transfer learning accurately classify COVID19 lung infection MESHD on portable chest radiographs

    Authors: Shreeja Kikkisetti; Jocelyn Zhu; Beiyi Shen; Haifang Li; Tim Duong; Peng Wang; Xu Zhang; Kangli Cui; Tingting Tao; Zhongyu Li; Wenwen Chen; Yongtang Zheng; Jianhua Qin; Zhiqiang Ku; Zhiqiang An; Birte Kalveram; Alexander N Freiberg; Vineet D Menachery; Xuping Xie; Kenneth S Plante; Scott C Weaver; Pei-Yong Shi; Pieter S. Hiemstra; Bruce A. Ponder; Mika J Makela; Kristiina Malmstrom; Robert C. Rintoul; Paul A. Reyfman; Fabian J. Theis; Corry-A Brandsma; Ian Adcock; Wim Timens; Cheng J. Xu; Maarten van den Berge; Roland F. Schwarz; Gerard H. Koppelman; Martijn C. Nawijn; Alen Faiz

    doi:10.1101/2020.09.02.20186759 Date: 2020-09-02 Source: medRxiv

    Portable chest x-ray (pCXR) has become an indispensable tool in the management of Coronavirus Disease MESHD 2019 (COVID-19) lung infection MESHD. This study employed deep-learning convolutional neural networks to classify COVID-19 lung infections on pCXR from normal and related lung infections MESHD to potentially enable more timely and accurate diagnosis. This retrospect study employed deep-learning convolutional neural network (CNN) with transfer learning to classify based on pCXRs COVID-19 pneumonia HP pneumonia MESHD (N=455) on pCXR from normal (N=532), bacterial pneumonia MESHD pneumonia HP (N=492), and non-COVID viral pneumonia MESHD pneumonia HP (N=552). The data was split into 75% training and 25% testing. A five-fold cross-validation was used. Performance SERO was evaluated using receiver-operating curve analysis. Comparison was made with CNN operated on the whole pCXR and segmented lungs. CNN accurately classified COVID-19 pCXR from those of normal, bacterial pneumonia MESHD pneumonia HP, and non-COVID-19 viral pneumonia MESHD pneumonia HP patients in a multiclass model. The overall sensitivity SERO, specificity, accuracy, and AUC were 0.79, 0.93, and 0.79, 0.85 respectively (whole pCXR), and were 0.91, 0.93, 0.88, and 0.89 (CXR of segmented lung). The performance SERO was generally better using segmented lungs. Heatmaps showed that CNN accurately localized areas of hazy appearance, ground glass opacity and/or consolidation on the pCXR. Deep-learning convolutional neural network with transfer learning accurately classifies COVID-19 on portable chest x-ray against normal, bacterial pneumonia MESHD pneumonia HP or non-COVID viral pneumonia MESHD pneumonia HP. This approach has the potential to help radiologists and frontline physicians by providing more timely and accurate diagnosis.

    74 Days Dynamic Changes of Chest CT Images of Coronavirus Disease MESHD 2019 (COVID-19) in Hebei Province, China

    Authors: jianqin Liang; Guizeng Liu; Shuzhuang Yu; Yang Yang; Yanchun Li; Hongli Tian; Zhe Chen

    doi:10.21203/rs.3.rs-70721/v1 Date: 2020-09-02 Source: ResearchSquare

    Background Since December 2019, the COVID-19 infection broke MESHD out in many parts of the world with confirmed and death MESHD cases rapidly increasing, which posed a great threat to human life and health. Current nucleic acid detection and antibody testing SERO for the SARS-CoV-2 were the main methods for diagnosis of COVID-19, but not so sensitive, with high false negative rate and missed diagnosis rate. Imaging changes of COVID-19 not only precede symptomatic changes, but also have different imaging characteristics in different periods. We conducted 74 days of dynamic chest CT imaging observation on COVID-19 patients in Hebei province, aiming to understand the dynamic characteristics of the chest CT changes of COVID-19, so as to find the source of infection early, take early intervention measures, and judge the prognosis. Methods Chest CT examinations at intervals 1 to 4 days were conducted for 11 patients with a diagnosis of COVID-19. On the 74th day after onset, chest CT was reexamined to analyze the characteristics of chest CT in each stage. Results Of the 11 cases, 1 case was imported from Wuhan, 10 cases were infected for family clustering after close contact TRANS with confirmed COVID-19 cases. There were 3 ordinary cases, 3 severe cases and 5 critical cases. Among them, 2 critical cases died for old age TRANS and complications of underlying diseases MESHD, while 9 cases were cured by April 7, 2020. The changes of chest CT imaging in 1 child TRANS appeared prior to the clinical symptoms. 1–4 days after onset of the initial symptom were the early stages: Chest CT was mainly characterized by single lung quasi-circular ground glass shadow and fine mesh shadow. 5–10 days were the progressive stages: The lesion spread along the axial interstitium of the bronchi and gradually diffused to the whole lung, and reach the peak on day 6 to 9, which was characterized by consolidation, paving stone sign, halo sign, reversed halo sign, and even ‘white lung’ for the critical patients. The recovery stages began on day 11 after onset: The fiber cord, ground glass and consolidation shadow were gradually absorbed. After 74 days of follow-up, no serious permanent lung injury MESHD was found. Conclusion Chest CT could determine the different stages of COVID-19. Dynamic follow-up chest CT showed a good prognosis of COVID-19 in Hebei Province, China

    Symbolic Semantic Segmentation and Interpretation of COVID-19 Lung Infections in Chest CT volumes based on Emergent Languages

    Authors: Aritra Chowdhury; Alberto Santamaria-Pang; James R. Kubricht; Jianwei Qiu; Peter Tu

    id:2008.09866v1 Date: 2020-08-22 Source: arXiv

    The coronavirus disease MESHD (COVID-19) has resulted in a pandemic crippling the a breadth of services critical to daily life. Segmentation of lung infections MESHD in computerized tomography (CT) slices could be be used to improve diagnosis and understanding of COVID-19 in patients. Deep learning systems lack interpretability because of their black box nature. Inspired by human communication of complex ideas through language, we propose a symbolic framework based on emergent languages for the segmentation of COVID-19 infections in CT scans of lungs. We model the cooperation between two artificial agents - a Sender and a Receiver. These agents synergistically cooperate using emergent symbolic language to solve the task of semantic segmentation. Our game theoretic approach is to model the cooperation between agents unlike Generative Adversarial Networks (GANs). The Sender retrieves information from one of the higher layers of the deep network and generates a symbolic sentence sampled from a categorical distribution of vocabularies. The Receiver ingests the stream of symbols and cogenerates the segmentation mask. A private emergent language is developed that forms the communication channel used to describe the task of segmentation of COVID infections. We augment existing state of the art semantic segmentation architectures with our symbolic generator to form symbolic segmentation models. Our symbolic segmentation framework achieves state of the art performance SERO for segmentation of lung infections MESHD caused by COVID-19. Our results show direct interpretation of symbolic sentences to discriminate between normal and infected regions, infection MESHD morphology and image characteristics. We show state of the art results for segmentation of COVID-19 lung infections MESHD in CT.

    Pulmonary Cavitation – An Under-recognized Late Complication of Severe COVID-19 Lung Disease MESHD

    Authors: Zaid Zoumot; Maria-Fernanda Bonilla; Ali S. Wahla; Irfan Shafiq; Mateen Uzbeck; Rania M. El-Lababidi; Fadi Hamed; Mohamed Abuzakouk; Mahmoud ElKaissi

    doi:10.21203/rs.3.rs-62904/v1 Date: 2020-08-20 Source: ResearchSquare

    Background: Pulmonary radiological findings of the novel coronavirus disease MESHD 2019 (COVID-19) have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill. However, lung cavitation has not been commonly described in these patients. The objective of this study was to assess the incidence of pulmonary cavitation MESHD in patients with COVID-19 and describe its characteristics and evolution.Methods: We conducted a retrospective review of all patients admitted to our institution with COVID-19 and reviewed electronic medical records and imaging to identify patients who developed pulmonary cavitation.Results: Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary cavitation, comprising 3.3% (n=12/359) of patients who developed COVID-19 pneumonia HP pneumonia MESHD, and 11% (n=12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died, two are recovering in hospital and four have been discharged home.  Conclusion: Cavitary lung disease MESHD in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.

    The involvement of Central Nervous System and sequence variability of Severe Adult Respiratory Syndrome MESHD Adult TRANS Respiratory Syndrome – Coronavirus-2 revealed in autopsy tissue samples: a case report.

    Authors: Lis Høy Marbjerg; Christina Jacobsen; Jannik Fonager; Claus Bøgelund; Morten Rasmussen; Anders Fomsgaard; Jytte Banner; Veronika Vorobieva Solholm Jensen

    doi:10.21203/rs.3.rs-61471/v1 Date: 2020-08-18 Source: ResearchSquare

    Background: The case presented here illustrates that interdisciplinary teamwork can be essential for the understanding of the COVID-19 disease presentation and enlightening of the pathophysiology. Case presentation: A 60-years-old overweight HP woman without any comorbidities was found dead in her apartment after 14 days of home isolation due to suspicion on the Coronavirus disease MESHD 2019 (COVID-19). She had reported symptoms of tachycardia HP tachycardia MESHD, fever HP fever MESHD, and increasing respiratory difficulty one day before her death MESHD. Due to the Danish legal act on sudden deaths a forensic autopsy was performed including a thorough examination and biosampling. The results of the forensic autopsy displayed sever densified, almost airless, firm lungs, and an unspecific reactive minimal focal perivascular inflammation MESHD consisting of macrophages of the brain tissue. The final diagnosis, COVID-19 with involvement of the central nervous system was established by use of the RT-RNA analysis on cerebrospinal fluid, as well as by serologic detection of the specific antibodies for SARS-CoV-2 SERO in cerebrospinal fluid and serum SERO. The genetic analysis displayed a 2 % variation between SARS-CoV-2 isolates recovered from the tracheal sample, cerebrospinal fluid, and tissues from both lungs.Conclusion: The combination of all available results revealed that the cause of death MESHD was COVID-19 with severe pulmonary disease MESHD and neuroinvasion, as well as renal affection resulting in hyponatremia HP hyponatremia MESHD. To our knowledge, it was not shown previously that neuroinvasion could be confirmed by the detection of specific antibodies for SARS-CoV-2 SERO and SARS-CoV-2 specific RNA in cerebrospinal fluid. This case supports hypotheses that SARS-CoV-2 may cause central nervous system infection MESHD. The genetic distinction between SARS-CoV-2 isolates was done by whole-genome sequencing, where the isolate recovered from the cerebrospinal fluid was the most different. 

    Pulmonary cavitation; an under-recognized late complication of severe COVID-19 lung disease MESHD

    Authors: Zaid Zoumot; Maria-Fernanda Bonilla; Ali Saeed Wahla; Irfan Shafiq; Mateen Uzbeck; Rania M El-Lababidi; Fadi Hamed; Mohamed Abuzakouk; Mahmoud El-Kaissi; Xiaoyang Ma; Tianwei Zhao; Xiaodi Guo; Zhihai Chen; Arjun Rustagi; Angela J Rogers; Nigam H Shah; Catherine A Blish; Jennifer R Cochran; Kari C Nadeau; Theodore S Jardetzky; James L Zehnder; Taia T Wang; Peter S Kim; Saurabh Gombar; Robert Tibshirani; Benjamin A Pinsky; Scott D Boyd

    doi:10.1101/2020.08.15.20175869 Date: 2020-08-17 Source: medRxiv

    Background: Radiological findings of the novel coronavirus disease MESHD 2019 (COVID-19) pulmonary disease MESHD have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill, however, lung cavitation has not been described in these patients. Objectives: To assess the incidence of pulmonary cavitation MESHD and describe its characteristics and evolution. Methods: A retrospective review of all patients admitted to our institution with COVID-19 was undertaken and imaging reviewed to identify patients who developed pulmonary cavitation. Results: Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary cavitation, comprising 3.3% (n=12/359) of those with COVID-19 pneumonia HP pneumonia MESHD, and 11% (n=12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died while another remains critically ill and unlikely to survive. Conclusion: Cavitary lung disease MESHD in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.